Ryan Scott

Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

Zachary Frosch, MD, MSHP, discusses the investigation of travel burden/costs related to bispecific antibodies in diffuse large B-cell lymphoma or follicular lymphoma.

Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

John Mascarenhas, MD, discusses navtemadlin's mechanism of action and its potential to shift the myelofibrosis treatment landscape

Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.

Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.

Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.

Cathy Eng, MD, FACP, FASCO, shares insights on biomarker testing and sequencing strategies for patients with colorectal cancer.

Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.

Glenn J. Hanna, MD, discusses data with PYX-201, expanding on the phase 1 trial which evaluated the agent in head and neck squamous cell carcinoma.

Jennifer Amengual, MD, discusses real-world outcomes with CAR T-cell therapy and bispecific antibodies in patients with DLBCL.

NDI-101150 monotherapy demonstrated antitumor activity and was well tolerated among patients with heavily pretreated renal cell carcinoma.

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

Suneel Kamath, MD, took to the OncLive X (Twitter) account during Pancreatic Cancer Awareness Month to share the importance of recognizing this disease.

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Health Canada has approved cilta-cel for use in patients with relapsed/lenalidomide-refractory multiple myeloma following 1 to 3 prior lines of therapy.

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.